Prostate cancer chemoprevention

Gurdarshan S. Sandhu; Kenneth G. Nepple; Youssef S. Tanagho; Gerald L. Andriole

doi:10.1053/j.seminoncol.2013.04.003

Prostate cancer chemoprevention

Gurdarshan S. Sandhu, Kenneth G. Nepple, Youssef S. Tanagho, Gerald L. Andriole

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Prostate cancer is a leading cause of morbidity and mortality in men and has significant treatment-associated complications. Prostate cancer chemoprevention has the potential to decrease the morbidity and mortality associated with this disease. Chemoprevention research to date has primarily focused on nutrients and 5 alpha-reductase inhibitors (5ARIs). A large randomized trial (SELECT) found no favorable effect of selenium or vitamin E on prostate cancer prevention. Two large randomized placebo controlled trials (the PCPT and REDUCE trials) have been published and have supported the role of 5ARIs in prostate cancer chemoprevention; however, these trials also have prompted concerns regarding the increase in high-grade disease seen with treatment and have not been approved by the US Food and Drug Administration (FDA) for chemoprevention. Conclusive evidence for the chemopreventive benefit of nutrients or vitamins is lacking, whereas the future role of 5ARIs remains to be clarified.

Original language	English
Pages (from-to)	276-285
Number of pages	10
Journal	Seminars in Oncology
Volume	40
Issue number	3
DOIs	https://doi.org/10.1053/j.seminoncol.2013.04.003
State	Published - Jun 2013

Access to Document

10.1053/j.seminoncol.2013.04.003

Cite this

@article{1e681c467ccf4477b6f7abb63b5e6cad,

title = "Prostate cancer chemoprevention",

abstract = "Prostate cancer is a leading cause of morbidity and mortality in men and has significant treatment-associated complications. Prostate cancer chemoprevention has the potential to decrease the morbidity and mortality associated with this disease. Chemoprevention research to date has primarily focused on nutrients and 5 alpha-reductase inhibitors (5ARIs). A large randomized trial (SELECT) found no favorable effect of selenium or vitamin E on prostate cancer prevention. Two large randomized placebo controlled trials (the PCPT and REDUCE trials) have been published and have supported the role of 5ARIs in prostate cancer chemoprevention; however, these trials also have prompted concerns regarding the increase in high-grade disease seen with treatment and have not been approved by the US Food and Drug Administration (FDA) for chemoprevention. Conclusive evidence for the chemopreventive benefit of nutrients or vitamins is lacking, whereas the future role of 5ARIs remains to be clarified.",

author = "Sandhu, {Gurdarshan S.} and Nepple, {Kenneth G.} and Tanagho, {Youssef S.} and Andriole, {Gerald L.}",

year = "2013",

month = jun,

doi = "10.1053/j.seminoncol.2013.04.003",

language = "English",

volume = "40",

pages = "276--285",

journal = "Seminars in Oncology",

issn = "0093-7754",

number = "3",

}

TY - JOUR

T1 - Prostate cancer chemoprevention

AU - Sandhu, Gurdarshan S.

AU - Nepple, Kenneth G.

AU - Tanagho, Youssef S.

AU - Andriole, Gerald L.

PY - 2013/6

Y1 - 2013/6

N2 - Prostate cancer is a leading cause of morbidity and mortality in men and has significant treatment-associated complications. Prostate cancer chemoprevention has the potential to decrease the morbidity and mortality associated with this disease. Chemoprevention research to date has primarily focused on nutrients and 5 alpha-reductase inhibitors (5ARIs). A large randomized trial (SELECT) found no favorable effect of selenium or vitamin E on prostate cancer prevention. Two large randomized placebo controlled trials (the PCPT and REDUCE trials) have been published and have supported the role of 5ARIs in prostate cancer chemoprevention; however, these trials also have prompted concerns regarding the increase in high-grade disease seen with treatment and have not been approved by the US Food and Drug Administration (FDA) for chemoprevention. Conclusive evidence for the chemopreventive benefit of nutrients or vitamins is lacking, whereas the future role of 5ARIs remains to be clarified.

AB - Prostate cancer is a leading cause of morbidity and mortality in men and has significant treatment-associated complications. Prostate cancer chemoprevention has the potential to decrease the morbidity and mortality associated with this disease. Chemoprevention research to date has primarily focused on nutrients and 5 alpha-reductase inhibitors (5ARIs). A large randomized trial (SELECT) found no favorable effect of selenium or vitamin E on prostate cancer prevention. Two large randomized placebo controlled trials (the PCPT and REDUCE trials) have been published and have supported the role of 5ARIs in prostate cancer chemoprevention; however, these trials also have prompted concerns regarding the increase in high-grade disease seen with treatment and have not been approved by the US Food and Drug Administration (FDA) for chemoprevention. Conclusive evidence for the chemopreventive benefit of nutrients or vitamins is lacking, whereas the future role of 5ARIs remains to be clarified.

UR - http://www.scopus.com/inward/record.url?scp=84879434018&partnerID=8YFLogxK

U2 - 10.1053/j.seminoncol.2013.04.003

DO - 10.1053/j.seminoncol.2013.04.003

M3 - Article

C2 - 23806493

AN - SCOPUS:84879434018

SN - 0093-7754

VL - 40

SP - 276

EP - 285

JO - Seminars in Oncology

JF - Seminars in Oncology

IS - 3

ER -

Prostate cancer chemoprevention

Abstract

Access to Document

Other files and links

Fingerprint

Cite this